Brought to you by 
Clovis Oncology nets $129mm in initial public offering
30 Nov 2011
Executive Summary
Specialty cancer pharmaco Clovis Oncology Inc. has netted $129mm in its initial public offering of 10.7mm shares (including partial exercise of the overallotment) at $13, the low end of its $13-15 price range. The company initially planned to sell only 9.3mm shares. Existing stockholders, directors, and executive management have agreed to buy 4.3mm, or 43%, of the shares at the IPO price.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clovis Oncology nets $129mm in initial public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice